Improved survival of HER2+ breast cancer patients treated with trastuzumab and chemotherapy is associated with host antibody immunity against the HER2 intracellular domain

Cancer Research

Volumn 76, Issue 13, 2016, Pages 3702-3710

  Knutson, Keith L ^a   Clynes, Raphael ^b   Shreeder, Barath ^a   Yeramian, Patrick ^c   Kemp, Kathleen P ^c   Ballman, Karla ^d   Tenner, Kathleen S ^d   Erskine, Courtney L ^e   Norton, Nadine ^a   Northfelt, Donald ^f   Tan, Winston ^a   Calfa, Carmen ^g   Pegram, Mark ^h   Mittendorf, Elizabeth A ⁱ   Perez, Edith A ^a  

^a MAYO CLINIC   (United States)

^b Columbia University ^*  (United States)

^c Vaccine and Gene Therapy Institute of Florida   (United States)

^d MAYO CLINIC   (United States)

^e MAYO GRADUATE SCHOOL   (United States)

^f MAYO CLINIC   (United States)

^g MEMORIAL REGIONAL HOSPITAL   (United States)

^h STANFORD UNIVERSITY   (United States)

ⁱ UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CARBOPLATIN; CARCINOEMBRYONIC ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; NAVELBINE; PACLITAXEL; PROTEIN P53; SOMATOMEDIN BINDING PROTEIN 2; TRASTUZUMAB; TUMOR ANTIGEN; ANTINEOPLASTIC AGENT; TUMOR MARKER; VINBLASTINE; VINORELBINE TARTRATE;

ADAPTIVE IMMUNITY; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; CORRELATIONAL STUDY; EPIDERMAL GROWTH FACTOR RECEPTOR 2 POSITIVE BREAST CANCER; EXTRACELLULAR SPACE; FEMALE; HUMAN; INTRACELLULAR SPACE; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN DOMAIN; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT DURATION; ANALOGS AND DERIVATIVES; BREAST NEOPLASMS; CANCER STAGING; CASE CONTROL STUDY; CLINICAL TRIAL; COMPARATIVE STUDY; FOLLOW UP; IMMUNIZATION; IMMUNOLOGY; METABOLISM; MORTALITY; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PROGNOSIS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, TUMOR; BREAST NEOPLASMS; CAPECITABINE; CARBOPLATIN; CASE-CONTROL STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNIZATION; NEOPLASM STAGING; PACLITAXEL; PROGNOSIS; PROSPECTIVE STUDIES; RECEPTOR, ERBB-2; SURVIVAL RATE; TRASTUZUMAB; VINBLASTINE;

EID: 84977586676     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-15-3091     Document Type: Article

References (30)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014;64:9-29.
2. De Santis C, Ma J, Bryan L, Jemal A. Breast cancer statistics, 2013. CA Cancer J Clin 2014;64:52-62.
3. Moasser MM. The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene 2007;26:6469-87.
4. Sliwkowski MX, Mellman I. Antibody therapeutics in cancer. Science 2013;341:1192-8.
5. Rexer BN, Arteaga CL. Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer: mechanisms and clinical implications. Crit Rev Oncog 2012;17:1-16.
6. Taylor C, Hershman D, Shah N, Suciu-Foca N, Petrylak DP, Taub R, et al. Augmented HER-2 specific immunity during treatment with trastuzumab and chemotherapy. Clin Cancer Res 2007;13:5133-43.
7. Crotty S. A brief history of T cell help to B cells. Nat Rev Immunol 2015;15:185-9.
8. Tan WW, Allred JB, Salim M, Flynn P, Fishkin PA, Stella PJ, et al. Phase II interventional study (N0337) of capecitabine in combination with vinorelbine and trastuzumabfor first- or second-line treatment of HER2-positive metastatic breast cancer: a north central cancer treatment group trial. Clin Breast Cancer 2012;12:81-6.
9. Perez EA, Suman VJ, Rowland KM, Ingle JN, Salim M, Loprinzi CL, et al. Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing meta static breast cancer: NCCTG study 983252. Clin Breast Cancer 2005;6:425-32.
10. Disis ML, Knutson KL, Schiffman K, Rinn K, McNeel DG. Pre-existent immunity to the HER-2/neu oncogenic protein in patients with HER-2/neu overexpressing breast and ovarian cancer. Breast Cancer Res Treat 2000;62:245-52.
11. Guilliams M, Bruhns P, Saeys Y, Hammad H, Lambrecht BN. The function of Fcgamma receptors in dendritic cells and macrophages. Nat Rev Immunol 2014;14:94-108.
12. Knutson KL, Perez EA, Ballman KV, Erskine CL, Fox N, McCarl C, et al. Generation of adaptive HER2-specific immunity in HER2 breast cancer patients by addition of trastuzumab to chemotherapy in the adjuvant setting: NCCTG (Alliance) study N9831. J Clin Oncol 31, 2013 (suppl; abstr 522).
13. Park S, Jiang Z, Mortenson ED, Deng L, Radkevich-Brown O, Yang X, et al. The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity. Cancer Cell 2010;18:160-70.
14. Lehmann PV, Sercarz EE, Forsthuber T, Dayan CM, Gammon G. Determinant spreading and the dynamics of the autoimmune T-cell repertoire. Immunol Today 1993;14:203-8.
15. Disis ML, Gooley TA, Rinn K, Davis D, Piepkorn M, Cheever MA, et al. Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. J Clin Oncol 2002;20:2624-32.
16. Disis ML, Goodell V, Schiffman K, Knutson KL. Humoral epitope-spreading following immunization with a HER-2/neu peptide based vaccine in cancer patients. J Clin Immunol 2004;24:571-8.
17. Vanderlugt CL, Miller SD. Epitope spreading in immune-mediated diseases: implications for immunotherapy. Nat Rev Immunol 2002; 2:85-95.
18. Butterfield LH, Ribas A, Dissette VB, Amarnani SN, Vu HT, Oseguera D, et al. Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma. Clin Cancer Res 2003;9:998-1008.
19. Disis ML, Wallace DR, Gooley TA, Dang Y, Slota M, Lu H, et al. Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer. J Clin Oncol 2009;27:4685-92.
20. Wierecky J, Muller MR, Wirths S, Halder-Oehler E, Dorfel D, Schmidt SM, et al. Immunologic and clinical responses after vaccinations with peptidepulsed dendritic cells in metastatic renal cancer patients. Cancer Res 2006;66:5910-8.
21. Jager E, Stockert E, Zidianakis Z, Chen YT, Karbach J, Jager D, et al. Humoral immune responses of cancer patients against "Cancer-Testis" antigen NY-ESO-1: correlation with clinical events. Int J Cancer 1999;84:506-10.
22. Stockert E, Jager E, Chen YT, Scanlan MJ, Gout I, Karbach J, et al. A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J Exp Med 1998;187:1349-54.
23. Bargmann CI, Hung MC, Weinberg RA. The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature 1986;319: 226-30.
24. Goodell V, Salazar LG, Urban N, Drescher CW, Gray H, Swensen RE, et al. Antibody immunity to the p53 oncogenic protein is a prognostic indicator in ovarian cancer. J Clin Oncol 2006;24:762-8.
25. von Mensdorff-Pouilly S, Verstraeten AA, Kenemans P, Snijdewint FG, Kok A, Van Kamp GJ, et al. Survival in early breast cancer patients is favorably influenced by a natural humoral immune response to polymorphic epithelial mucin. J Clin Oncol 2000;18:574-83.
26. Lower EE, Glass E, Blau R, Harman S. HER-2/neu expression in primary and metastatic breast cancer. Breast Cancer Res Treat 2009;113:301-6.
27. Sharma A, Koldovsky U, Xu S, Mick R, Roses R, Fitzpatrick E, et al. HER-2 pulsed dendritic cell vaccine can eliminate HER-2 expression and impact ductal carcinoma in situ. Cancer 2012;118:4354-62.
28. Czerniecki BJ, Koski GK, Koldovsky U, Xu S, Cohen PA, Mick R, et al. Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion. Cancer Res 2007;67:1842-52.
29. Nowak AK, Robinson BW, Lake RA. Gemcitabine exerts a selective effect on the humoral immune response: implications for combination chemoimmunotherapy. Cancer Res 2002;62:2353-8.
30. Schafer AI, Churchill WH, Ames P, Weinstein L. The influence of chemotherapy on response of patients with hematologic malignancies to influenza vaccine. Cancer 1979;43:25-30.